-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $232

Benzinga·03/19/2026 17:48:53
Listen to the news
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $219 to $232.